Several reports have suggested an increased risk of malignant lymphoma in patients with rheumatoid arthritis treated with methotrexate (MTX). We herein describe the case of a 71-year-old woman with rheumatoid arthritis who developed MYC/BCL2 double-hit lymphoma associated with MTX therapy. She developed a fever and lymphadenopathies over a 2-week period and had elevated levels of soluble IL-2 receptor. Inguinal lymph node and bone marrow biopsies showed diffuse large B cell lymphoma. Fluorescent in situ hybridization revealed MYC and BCL2 gene rearrangements in her lymphoma cells. Accordingly, a diagnosis of MYC/ BCL2 double-hit lymphoma was made. This is the first reported case of a double-hit lymphoma associated with MTX therapy.
CITATION STYLE
Kurimoto, R., Shono, K., Onoda, M., Yamamoto, K., & Yokota, A. (2016). MYC/BCL2 double-hit lymphoma in a patient with rheumatoid arthritis associated with methotrexate treatment. Internal Medicine, 55(16), 2271–2275. https://doi.org/10.2169/internalmedicine.55.6156
Mendeley helps you to discover research relevant for your work.